Preemptive Pharmacogenetic-Guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery: The Preemptive Pharmacogenetic-Guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery Pilot Trial

被引:1
|
作者
Staben, Rae [1 ]
Vnencak-Jones, Cindy L. [2 ]
Shi, Yaping [3 ]
Shotwell, Matthew S. [1 ,3 ]
Absi, Tarek [4 ]
Shah, Ashish S. [4 ]
Wanderer, Jonathan P. [1 ,5 ]
Beller, Marc [6 ]
Kertai, Miklos D. [1 ,7 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA
[3] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA
[4] Vanderbilt Univ, Med Ctr, Dept Cardiac Surg, Nashville, TN USA
[5] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN USA
[6] Vanderbilt Univ, Med Ctr, Ctr Precis Med, Nashville, TN USA
[7] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, 1211 21st Ave South,MAB 526, Nashville, TN 37212 USA
关键词
atrial fibrillation; cardiac surgery; beta-blockers; pharmacogenetic testing; CYP2D6; GENOTYPE; METABOLIZERS; ASSOCIATION; PHENOTYPE; RISK;
D O I
10.1053/j.jvca.2023.06.017
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objectives: To test the hypothesis that implementation of a cytochrome P-450 2D6 (CYP2D6) genotype guided perioperative metoprolol administration will reduce the risk of postoperative atrial fibrillation (AF), the authors conducted the Preemptive Pharmacogenetic-Guided Metoprolol Management for Atrial Fibrillation in Cardiac Surgery pilot study. Design: Clinical pilot trial. Setting: Single academic center. Participants: Seventy-three cardiac surgery patients. Measurements and Main Results: Patients were classified as normal, intermediate, poor, or ultrarapid metabolizers after testing for their CYP2D6 genotype. A clinical decision support tool in the electronic health record advised providers on CYP2D6 genotype guided metoprolol dosing. Using historical data, the Bayesian method was used to compare the incidence of postoperative AF in patients with altered metabolizer status to the reference incidence. A logistic regression analysis was performed to study the association between the metabolizer status and postoperative AF while controlling for the Multicenter Study of Perioperative Ischemia AF Risk Index. Of the 73 patients, 30% (n = 22) developed postoperative AF; 89% (n = 65) were normal metabolizers; 11% (n = 8) were poor/intermediate metabolizers; and there were no ultrarapid metabolizer patients identified. The estimated rate of postoperative AF in patients with altered metabolizer status was 30% (95% CI 8%-60%), compared with the historical reference incidence (27%). In the risk-adjusted analysis, there was insufficient evidence to conclude that modifying metoprolol dosing based on poor/intermediate metabolizer status was associated significantly with the odds of postoperative AF (odds ratio 0.82, 95% CI 0.15-4.55, p = 0.82). Conclusions: A CYP2D6 genotype guided metoprolol management was not associated with a reduction of postoperative AF after cardiac surgery. (c) 2023 Published by Elsevier Inc.
引用
收藏
页码:1974 / 1982
页数:9
相关论文
共 50 条
  • [1] CYP2D6 Genotype-guided Metoprolol Therapy in Cardiac Surgery Patients: Rationale and Design of the Pharmacogenetic-guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) Pilot Study
    Dunham, Wills C.
    Weinger, Matthew B.
    Slagle, Jason
    Pretorius, Mias
    Shah, Ashish S.
    Absi, Tarek S.
    Shotwell, Matthew S.
    Beller, Marc
    Thomas, Erica
    Vnencak-Jones, Cindy L.
    Freundlich, Robert E.
    Wanderer, Jonathan P.
    Sandberg, Warren S.
    Kertai, Miklos D.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2020, 34 (01) : 20 - 28
  • [2] Cost-Effectiveness of Pharmacogenetic-Guided Dosing of Phenprocoumon in Atrial Fibrillation
    Verhoef, Talitha I.
    Redekop, William K.
    Veenstra, David L.
    Thariani, Rahber
    Beltman, Peter A.
    van Schie, Rianne M. F.
    de Boer, Anthonius
    Maitland-van der Zee, Anke-Hilse
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 328 - 329
  • [3] Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation
    Verhoef, Talitha I.
    Redekop, William K.
    Veenstra, David L.
    Thariani, Rahber
    Beltman, Peter A.
    van Schie, Rianne M. F.
    de Boer, Anthonius
    Maitland-van der Zee, Anke-Hilse
    PHARMACOGENOMICS, 2013, 14 (08) : 869 - 883
  • [4] Management of Postoperative Atrial Fibrillation in Cardiac Surgery Patients
    Raiten, Jesse
    Patel, Prakash A.
    Gutsche, Jacob
    SEMINARS IN CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2015, 19 (02) : 122 - 129
  • [5] Management of postoperative atrial fibrillation after cardiac surgery
    Ha, Andrew C. T.
    Mazer, Cyril David
    Verma, Subodh
    Yanagawa, Bobby
    Verma, Atul
    CURRENT OPINION IN CARDIOLOGY, 2016, 31 (02) : 183 - 190
  • [6] Metoprolol Versus Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery A Randomized Trial
    Halonen, Jari
    Loponen, Pertti
    Jarvinen, Otso
    Karjalainen, Jari
    Parviainen, Ilkka
    Halonen, Pirjo
    Magga, Jarkko
    Turpeinen, Anu
    Hippelainen, Mikko
    Hartikainen, Juha
    Hakala, Tapio
    ANNALS OF INTERNAL MEDICINE, 2010, 153 (11) : 703 - 709
  • [7] Update on Management of Postoperative Atrial Fibrillation After Cardiac Surgery
    Ronsoni, Rafael de March
    Marques Souza, Arthur Zanfrilli
    Luz Leiria, Tiago Luiz
    de Lima, Gustavo Glotz
    BRAZILIAN JOURNAL OF CARDIOVASCULAR SURGERY, 2020, 35 (02) : 206 - 210
  • [8] The management of atrial fibrillation after cardiac surgery
    Rho, Robert W.
    HEART, 2009, 95 (05) : 422 - 429
  • [9] Management of atrial fibrillation after cardiac surgery
    Conte, Sean M.
    Florisson, Daniel S.
    De Bono, Joshua A.
    Davies, Reece A.
    Newcomb, Andrew E.
    INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 656 - 658
  • [10] Postoperative Atrial Fibrillation and Cardiac Surgery
    Koza, Yavuzer
    CIRCULATION JOURNAL, 2014, 78 (01) : 264 - 264